Collaborative Arrangements and Licensing Agreements (Tables)

9 Months Ended

Sep. 30, 2020

Biogen [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2020 and 2019, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
SPINRAZA royalties (commercial revenue)	$	74.2		$	81.7		$	211.9		$	211.9
R&D revenue		51.2			25.5			98.6			81.9
Total revenue from our relationship with Biogen	$	125.4		$	107.2		$	310.5		$	293.8
Percentage of total revenue		78	%		64	%		71	%		47	%

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2020 and 2019, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
R&D revenue	$	3.8		$	6.6		$	34.3		$	14.3
Percentage of total revenue		2	%		4	%		8	%		2	%

Janssen Biotech, Inc. [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Relationship

During the three and nine months ended September 30, 2020, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):

	Three Months Ended September 30,			Nine Months Ended September 30,
	2020			2020
R&D revenue	$	5.0		$	5.0
Percentage of total revenue		3	%		1	%